JP6789283B2 - 改変酵母−ブラキュリー免疫療法組成物 - Google Patents

改変酵母−ブラキュリー免疫療法組成物 Download PDF

Info

Publication number
JP6789283B2
JP6789283B2 JP2018505476A JP2018505476A JP6789283B2 JP 6789283 B2 JP6789283 B2 JP 6789283B2 JP 2018505476 A JP2018505476 A JP 2018505476A JP 2018505476 A JP2018505476 A JP 2018505476A JP 6789283 B2 JP6789283 B2 JP 6789283B2
Authority
JP
Japan
Prior art keywords
yeast
bracury
cancer
bracully
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018505476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522041A5 (enExample
JP2018522041A (ja
Inventor
エイチ． キング、トーマス
エイチ． キング、トーマス
グオ、ジミン
シュロム、ジェフリー
パレナ、クラウディア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2018522041A publication Critical patent/JP2018522041A/ja
Publication of JP2018522041A5 publication Critical patent/JP2018522041A5/ja
Application granted granted Critical
Publication of JP6789283B2 publication Critical patent/JP6789283B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018505476A 2015-08-03 2016-08-01 改変酵母−ブラキュリー免疫療法組成物 Active JP6789283B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200497P 2015-08-03 2015-08-03
US62/200,497 2015-08-03
PCT/US2016/044977 WO2017023840A1 (en) 2015-08-03 2016-08-01 Modified yeast-brachyury immunotherapeutic compositions

Publications (3)

Publication Number Publication Date
JP2018522041A JP2018522041A (ja) 2018-08-09
JP2018522041A5 JP2018522041A5 (enExample) 2019-09-12
JP6789283B2 true JP6789283B2 (ja) 2020-11-25

Family

ID=56618277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505476A Active JP6789283B2 (ja) 2015-08-03 2016-08-01 改変酵母−ブラキュリー免疫療法組成物

Country Status (11)

Country Link
US (1) US11065313B2 (enExample)
EP (1) EP3331552B1 (enExample)
JP (1) JP6789283B2 (enExample)
KR (1) KR102833272B1 (enExample)
CN (1) CN108348586B (enExample)
AU (1) AU2016303525B2 (enExample)
CA (1) CA2994272C (enExample)
HK (1) HK1249431A1 (enExample)
IL (1) IL257208B (enExample)
TW (1) TWI748957B (enExample)
WO (1) WO2017023840A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1216861A1 (zh) 2013-03-19 2016-12-09 Globeimmune, Inc. 基於酵母的脊索瘤免疫療法
KR102409372B1 (ko) * 2014-04-11 2022-06-16 글로브이뮨 효모 면역 요법 및 타입 i 인터페론 감도
KR20250107975A (ko) 2015-08-03 2025-07-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 브라큐리 결실 돌연변이체, 브라큐리 결실 돌연변이체를 인코딩하는 비-효모 벡터, 및 이들의 용도
WO2019222073A1 (en) * 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
WO2020112870A1 (en) 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
WO2022187963A1 (en) * 2021-03-10 2022-09-15 Provincial Health Services Authority Immunotherapy agents targeting brachyury and methods of using same
CA3247904A1 (en) * 2022-03-08 2023-09-14 Immunitybio, Inc. YEAST-BASED VACCINE INJECTED INTRATUMORALLY
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
DE69820291D1 (de) 1997-10-10 2004-01-15 Meyer Pharmaceuticals Llc Krebsimmuntherapie mittels allostimulierten zellen zur sequentiellen implantationsstrategie
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
DE60026584T2 (de) 2000-04-06 2007-03-08 SEER Pharamaceuticals, LLC, Fairfield Microbielles wirkstoffabgabesystem
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
ES2676503T3 (es) 2002-12-16 2018-07-20 Globeimmune, Inc. Vacunas basadas en levadura como inmunoterapia
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20060009404A1 (en) 2004-07-09 2006-01-12 Williams Jason R Tumor ablation in combination with pharmaceutical compositions
JP2009500454A (ja) 2005-07-11 2009-01-08 グローブイミューン， インコーポレイテッド 標的化治療の変異型を回避する免疫応答を惹起するための組成物および方法
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
BRPI0706913A2 (pt) 2006-02-02 2011-04-12 Globeimmune Inc vacina com base em levedura para induzir uma reação imune
CA2647102A1 (en) 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
AU2008214029B2 (en) 2007-02-02 2014-01-30 Globelmmune, Inc. Methods for producing yeast-based vaccines
EP2125868B1 (en) 2007-02-28 2015-06-10 The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
CN101730542A (zh) 2007-03-19 2010-06-09 环球免疫公司 用于靶向消除癌症靶向疗法的突变逃逸的组合物和方法
WO2009042642A2 (en) * 2007-09-24 2009-04-02 President And Fellows Of Harvard College Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
US10383924B2 (en) * 2009-04-17 2019-08-20 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
JP2013522302A (ja) 2010-03-14 2013-06-13 グローブイミューン，インコーポレイテッド 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
PH12013501683A1 (en) 2011-02-12 2019-07-17 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis b infection
PT2685995T (pt) 2011-03-17 2017-08-09 Globeimmune Inc Composições imunoterapêuticas de levedura-brachyury
JP2014523878A (ja) 2011-06-14 2014-09-18 グローブイミューン，インコーポレイテッド Ｄ型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法
CN104024429B (zh) * 2011-08-17 2019-06-04 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
HK1216861A1 (zh) 2013-03-19 2016-12-09 Globeimmune, Inc. 基於酵母的脊索瘤免疫療法

Also Published As

Publication number Publication date
WO2017023840A1 (en) 2017-02-09
TWI748957B (zh) 2021-12-11
IL257208A (en) 2018-03-29
KR102833272B1 (ko) 2025-07-10
US11065313B2 (en) 2021-07-20
CN108348586A (zh) 2018-07-31
IL257208B (en) 2021-10-31
KR20180054587A (ko) 2018-05-24
AU2016303525A1 (en) 2018-03-15
EP3331552A1 (en) 2018-06-13
TW201716574A (zh) 2017-05-16
CA2994272C (en) 2023-08-22
CA2994272A1 (en) 2017-02-09
AU2016303525B2 (en) 2021-01-21
JP2018522041A (ja) 2018-08-09
CN108348586B (zh) 2022-03-15
EP3331552B1 (en) 2021-01-27
US20180214525A1 (en) 2018-08-02
HK1249431A1 (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
JP6571822B2 (ja) 酵母−ｍｕｃ１免疫療法用組成物およびその使用
JP6580733B2 (ja) 酵母−ブラキュリ免疫治療組成物
JP6789283B2 (ja) 改変酵母−ブラキュリー免疫療法組成物
NZ724797B2 (en) Yeast-brachyury immunotherapeutic compositions
HK1192141B (en) Yeast-brachyury immunotherapeutic compositions
HK1192141A (en) Yeast-brachyury immunotherapeutic compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201102

R150 Certificate of patent or registration of utility model

Ref document number: 6789283

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250